Group 1: Financial Performance - The company's revenue for 2024 is projected to grow by 14.09% compared to 2023, driven by strong market demand and strategic focus on pharmaceutical packaging [2] - Research and development (R&D) investment for 2024 is set at 33.79 million RMB, reflecting a 12.16% increase from 2023 [3] Group 2: Business Strategy - The company aims to expand its production capacity and enhance market development efforts, particularly in pharmaceutical packaging [2][7] - Plans to accelerate the transformation of high borosilicate glass business and focus on new product development and channel expansion [4][7] Group 3: International Expansion - The company is prioritizing global development, with a focus on Latin America and the Middle East, having signed investment agreements in Egypt and Brazil [5][6] Group 4: Internal Management and Risk Mitigation - Continuous improvement in internal management is a key focus, including the introduction of high-level talent and enhancement of digital and automated processes to reduce production costs [8] - The company plans to establish independent subsidiaries for brand promotion and sales, enhancing its market presence [4][8] Group 5: Share Buyback Plan - The company has approved a share buyback plan, intending to repurchase between 50 million and 100 million RMB worth of its A-shares [9][10]

Group 1: Company Overview - The company is Shandong Linuo Medical Packaging Co., Ltd., with stock code 301188 and bond code 123221 [1]. Group 2: Investor Relations Activity - An investor relations activity was held on May 15, 2025, from 15:00 to 16:30 via an online platform [2]. - The meeting included a Q&A session where investors posed questions to the company representatives [2]. Group 3: Product Development and Branding - The company is establishing a high-end heat-resistant kitchen glass e-commerce brand in China, with a dedicated product design center and brand promotion center [2]. - A subsidiary has been set up in Hangzhou for promoting its own brands, including domestic brand "Lebole" and international brand "borohouse," which have been successfully registered and are being sold through domestic and international e-commerce channels [2]. Group 4: Growth Opportunities - The pharmaceutical packaging sector is experiencing significant growth opportunities, with strong market demand [3]. - The company plans to focus on expanding production capacity and enhancing market development efforts, particularly in high borosilicate heat-resistant glass products [3]. - Continuous development of new products and channels is emphasized to improve operational performance [3].